Equilis Te

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

toxoid tat-tetnu

Available from:

Intervet International BV

ATC code:

QI05AB03

INN (International Name):

Adjuvanted vaccine against tetanus

Therapeutic group:

Żwiemel

Therapeutic area:

Immunoloġiċi għall-equidae

Therapeutic indications:

Immunizzazzjoni attiva ta 'żwiemel li għandhom età ta' 6 xhur kontra t-tetnu biex tevita l-mortalità. Bidu ta 'immunità: 2 ġimgħat wara l-vaċċinazzjoni primarja courseDuration ta' l-immunità: 17-il xahar wara l-ewwel kors ta ' tilqim, 24 xahar wara l-ewwel revaċċinazzjoni.

Product summary:

Revision: 8

Authorization status:

Awtorizzat

Authorization date:

2005-07-08

Patient Information leaflet

                                11
11.
KUNDIZZJONIJIET
SPEĊJALI DWAR KIF GĦANDU JINĦAŻEN
Aħżen 2°C – 8°C , Ipproteġi mid-dawl. Tiffriżax
12.
PREKAWZJONIJIET
SPEĊJALI DWAR IR-RIMI TA’ PRODOTTI MHUX
UŻATI
JEW MATERJAL
IEĦOR GĦAR-RIMI, JEKK
IKUN
IL-KAŻ
Aqra l-fuljett ta’ tagħrif.
13.
IL-KLIEM
“GĦAL TRATTAMENT
TAL-ANNIMALI BISS” U KONDIZZJONIJIET
JEW RESTRIZZJONIJIET
DWAR IL-PROVISTA U L-UŻU, JEK K APPLIK ABBLI
Għal Trattament tal-Annimali
Biss - Għandu jingħata biss bi preskrizzjoni verterinarja.
14.
IL-KLIEM “ŻOMM
FEJN
MA JINTLAĦAQX U MA JIDHIRX MIT-TFAL”
Żomm fejn ma jidhirx u ma jintlaħaqx mit-tfal.
15.
L-ISEM U L-INDIRIZZ
TAS-SID TAL-AWTORIZZAZZJONI
TAL-KUMMERĊ
Intervet International B.V.
NL-5831 AN Boxmeer
16.
NUMRU/I TAL-AWTORIZZAZZJONI
TAL-KUMMERĊ
EU/2/05/055/001
EU/2/05/055/002
17.
NUMRU
TAL-LOTT
TAL-MANIFATTUR
Lott {numru}
12
TAGĦRIF MINIMU LI GĦANDU JIDHER FUQ UNITAJIET ŻGĦAR TA’ PPAKKJAR
LI
JMISS MAL-PRODOTT
Kunjett ta’ 1 ml u siringa ta’1ml mimlija
għall-lest
1.
ISEM
TAL-PRODOTT MEDIĊINALI VETERINARJU
Equilis Te [stampa ċara ta’ żiemel]
2.
KWANTITÀ
TAS-SUSTANZA(I) ATTIVA(I)
3.
KONTENUT
BĦALA PIŻ, VOLUM
JEW
NUMRU
TA’ DOŻI
1 doża
4.
MOD(I) TA’ AMMINISTRAZZJONI
IM
5.
ŻMIEN
TA’ TIŻMIM
Żmien ta’ tiżmim: Xejn ġranet
6.
NUMRU
TAL-LOTT
Lott {numru)
7.
DATA TA’ SKADENZA
Jiskadi {xahar/sena}
8.
IL-KLIEM
“
GĦALL-KURA TAL-ANNIMALI BISS”
Għall-kura tal-annimali
biss.
13
B. FULJETT
TA’ TAGĦRIF
14
FULJETT
TA’ TAGĦRIF
GĦAL
EQUILIS TE, SUSPENSJONI GĦALL-INJEZZJONI, GĦAŻ-ŻWIEMEL
1.
L-ISEM U L-INDIRIZZ
TAD-DETENTUR
TAL-AWTORIZZAZZJO NI
GĦAT-
TQEGĦID
FIS-SUQ U TAD-DETENTUR
TAL-AWTORIZZAZZJONI
GĦALL-
MANIFATTURA
RESPONSABBLI GĦALL-ĦRUĠ
TAL-LOTT,
JEKK
DIFFERENTI
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
L-Olanda
2.
ISEM
TAL-PRODOTT MEDIĊINALI VETERINARJU
Equilis Te, suspensjoni għall-injezzjoni, għaż-żwiemel
3.
DIKJARAZZJONI TAS-SUSTANZA(I)
ATTIVA(I) U
INGREDJENT(I)
OĦRA
Kull doża ta' 1ml fiha:
Sustanza Attiva :
Tetanus toxoid
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
KARATTERISTIĊI TAL-PRODOTT
FIL-QOSOR
2
1.
ISEM
TAL-PRODOTT MEDIĊINALI VETERINARJU
Equilis Te, suspensjoni għall-injezzjoni, għaż-żwiemel
2.
KOMPOŻIZZJONI
KWALITATTIVA
U KWANTITATTIVA
Kull
doża ta’ ml fiha:
Sustanza Attiva :
_Toxoid_
tat-tetnu
40 Lf
1
1
Qies ekwivalenti ta’ flokulazzjoni; jikkorispondu ma’ ≥30IU/ml
sirum tal-fenek tal-Indi fit-test ta’
potenza tal-Farmakopeja Ewropea
Sustanzi mhux attivi
Saponin ippurifikat
375 mikrogrammi
Kolesterol
125 mikrogrammi
Phosphatidylcholine
62.5 mikrogrammi
Għal-lista sħiħa tal-ingredjenti mhux attivi, ara s-sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Suspensjoni għal injezzjoni
Suspensjoni opalaxxenti ċara.
4.
TAGĦRIF
KLINIKU
4.1
SPEĊI LI FUQHOM SER JINTUŻA L-PRODOTT
Żwiemel
4.2
INDIKAZZJONIJIET GĦAL UŻU TAL-PRODOTT LI JISPEĊIFIKAW L-ISPEĊI LI
FUQHOM SE JINTUŻA L-PRODOTT.
Immunizzazzjoni attiva għal żwiemel ta’ sitt xhur jew aktar kontra
t-tetnu biex tippreveni l-imwiet.
Bidu ta’ immunità:
2 ġimgħat wara l-ewwel kors ta’ tilqim
Kemm iddum l-immunita:
17-il xahar wara l-ewwel kors ta’ tilqim
24 xahar wara l-ewwel revaċċinazzjoni
4.3
KONTRAINDIKAZZJONIJIET
Xejn.
4.4
TWISSIJIET SPEĊJALI GĦAL KULL SPEĊI LI GĦALIHA HU INDIKAT
IL-PRODOTT
Il-morien m’għandhomx jitlaqqmu qabel jagħlqu sitt xhur,
speċjalment jekk imwildin minn dwieb li
tlaqqmu għat-tieni darba fl-aħħar xahrejn ta’ tqala, għax hemm
il-possibilità li jinterferixxi mal-
antikorpi mill-omm.
4.5
PREKAWZJONIJIET SPEĊJALI GĦALL-UŻU
3
Annimali b’saħħithom biss għandhom jiġu mlaqqma.
Prekawzjonijiet speċjali li għandhom jittieħdu mill-persuna li
tamministra l-prodott mediċinali
veterinarju lill-annimali
F’każ li tinjetta lilek
innifsek, fittex parir mediku mal-ewwel u qis li turi l-fuljett ta’
informazzjoni fil-
pakkett jew it-tikketta lit-tabib.
4.6
EFFETTI MHUX MIXTIEQA (FREKWENZA U GRAVITÀ)
Nefħa iebsa jew ratba (dijametru mass. 5cm) tista’ tfeġġ fil-post
tal-injezzjoni, li tiċkien fi żmien
jumejn. F’każijiet rari, reaz
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 30-04-2020
Summary of Product characteristics Summary of Product characteristics Bulgarian 30-04-2020
Public Assessment Report Public Assessment Report Bulgarian 15-02-2021
Patient Information leaflet Patient Information leaflet Spanish 30-04-2020
Public Assessment Report Public Assessment Report Spanish 15-02-2021
Patient Information leaflet Patient Information leaflet Czech 30-04-2020
Public Assessment Report Public Assessment Report Czech 15-02-2021
Patient Information leaflet Patient Information leaflet Danish 30-04-2020
Public Assessment Report Public Assessment Report Danish 15-02-2021
Patient Information leaflet Patient Information leaflet German 30-04-2020
Public Assessment Report Public Assessment Report German 15-02-2021
Patient Information leaflet Patient Information leaflet Estonian 30-04-2020
Public Assessment Report Public Assessment Report Estonian 15-02-2021
Patient Information leaflet Patient Information leaflet Greek 30-04-2020
Public Assessment Report Public Assessment Report Greek 15-02-2021
Patient Information leaflet Patient Information leaflet English 30-04-2020
Public Assessment Report Public Assessment Report English 15-02-2021
Patient Information leaflet Patient Information leaflet French 30-04-2020
Public Assessment Report Public Assessment Report French 15-02-2021
Patient Information leaflet Patient Information leaflet Italian 30-04-2020
Public Assessment Report Public Assessment Report Italian 15-02-2021
Patient Information leaflet Patient Information leaflet Latvian 30-04-2020
Public Assessment Report Public Assessment Report Latvian 15-02-2021
Patient Information leaflet Patient Information leaflet Lithuanian 30-04-2020
Summary of Product characteristics Summary of Product characteristics Lithuanian 30-04-2020
Public Assessment Report Public Assessment Report Lithuanian 15-02-2021
Patient Information leaflet Patient Information leaflet Hungarian 30-04-2020
Summary of Product characteristics Summary of Product characteristics Hungarian 30-04-2020
Public Assessment Report Public Assessment Report Hungarian 15-02-2021
Patient Information leaflet Patient Information leaflet Dutch 30-04-2020
Public Assessment Report Public Assessment Report Dutch 15-02-2021
Patient Information leaflet Patient Information leaflet Polish 30-04-2020
Public Assessment Report Public Assessment Report Polish 15-02-2021
Patient Information leaflet Patient Information leaflet Portuguese 30-04-2020
Summary of Product characteristics Summary of Product characteristics Portuguese 30-04-2020
Public Assessment Report Public Assessment Report Portuguese 15-02-2021
Patient Information leaflet Patient Information leaflet Romanian 30-04-2020
Public Assessment Report Public Assessment Report Romanian 15-02-2021
Patient Information leaflet Patient Information leaflet Slovak 30-04-2020
Public Assessment Report Public Assessment Report Slovak 15-02-2021
Patient Information leaflet Patient Information leaflet Slovenian 30-04-2020
Summary of Product characteristics Summary of Product characteristics Slovenian 30-04-2020
Public Assessment Report Public Assessment Report Slovenian 15-02-2021
Patient Information leaflet Patient Information leaflet Finnish 30-04-2020
Public Assessment Report Public Assessment Report Finnish 15-02-2021
Patient Information leaflet Patient Information leaflet Swedish 30-04-2020
Public Assessment Report Public Assessment Report Swedish 15-02-2021
Patient Information leaflet Patient Information leaflet Norwegian 30-04-2020
Summary of Product characteristics Summary of Product characteristics Norwegian 30-04-2020
Patient Information leaflet Patient Information leaflet Icelandic 30-04-2020
Summary of Product characteristics Summary of Product characteristics Icelandic 30-04-2020
Patient Information leaflet Patient Information leaflet Croatian 30-04-2020
Public Assessment Report Public Assessment Report Croatian 15-02-2021

View documents history